Argenica Advances Late-stage Stroke Trial Preparations Following Positive Regulatory Progress
Argenica Therapeutics Limited (ASX: AGN) has reported significant progress in advancing its lead neuroprotective drug candidate, ARG-007 (xaranetide), towards a late-stage clinical trial for moderate to severe acute ischaemic stroke. During the quarter, the Company convened a global Clinical Advisory Committee to optimise the trial design, which will incorporate a precision medicine strategy and AI-enabled diagnostic tools to improve patient selection and trial efficiency. Argenica also completed all three additional assays requested by the U.S. Food and Drug Administration, with hERG, TNK and genotoxicity studies demonstrating favourable safety profiles. These outcomes position the Company to submit a comprehensive response to the FDA clinical hold and seek approval to commence a U.S. clinical trial. Additionally, the World Health Organisation approved xaranetide as the International Nonproprietary Name for ARG-007, while preclinical concussion studies confirmed its significant neuroprotective potential. Argenica ended the quarter with cash reserves of AU$6.35 million to support ongoing clinical development activities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Argenica Advances Late-stage Stroke Trial Preparations Following Positive Regulatory Progress
Argenica Therapeutics Limited (ASX: AGN) has reported significant progress in advancing its lead neuroprotective drug candidate, ARG-007 (xaranetide), towards a late-stage clinical trial for moderate to severe acute ischaemic stroke. During the quarter, the Company convened a global Clinical Advisory Committee to optimise the trial design, which will incorporate a precision medicine strategy and AI-enabled diagnostic tools to improve patient selection and trial efficiency. Argenica also completed all three additional assays requested by the U.S. Food and Drug Administration, with hERG, TNK and genotoxicity studies demonstrating favourable safety profiles. These outcomes position the Company to submit a comprehensive response to the FDA clinical hold and seek approval to commence a U.S. clinical trial. Additionally, the World Health Organisation approved xaranetide as the International Nonproprietary Name for ARG-007, while preclinical concussion studies confirmed its significant neuroprotective potential. Argenica ended the quarter with cash reserves of AU$6.35 million to support ongoing clinical development activities.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au